{"title":"他汀类药物对上皮性卵巢癌患者生存结局的影响","authors":"Pornpimon Nittiwatthanawit, Putsarat Insin, Putsarat Insin","doi":"10.1159/000545430","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Patients diagnosed with epithelial ovarian cancer (EOC) usually experience a poor prognosis with a 5-year survival rate of approximately 40%. Thus, there would be an interest in a new perspective on the anticancer action of statins on survival outcomes in patients with EOC. This study aimed to assess the effect of statin on survival outcomes in patients diagnosed with EOC.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted on EOC patients scheduled for cytoreductive surgery at Rajavithi Hospital between January 2012 and December 2016. Data on statin use before being diagnosed with EOC and cancer treatment were extracted from medical records. Survival outcomes, including progression-free survival (PFS) and overall survival (OS), were analyzed using the Kaplan-Meier method and log-rank test, comparing statin users and non-users. The Cox proportional hazards model was employed to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs) to determine the association between statin use and survival outcomes.</p><p><strong>Results: </strong>A total of 477 EOC patients met the inclusion criteria. Among them, 76 (15.9%) were statin users, while 401 (84.1%) were non-users. Over a median follow-up of 59 months, 210 patients (44%) experienced disease recurrence, and 197 (41.3%) succumbed to EOC. There was no statistically significant difference between statin users and non-users between 5-year PFS (45.1% vs. 56.1%, p = 0.295) and 5-year OS (50.8% vs. 55.3%, p = 0.590). Multivariate Cox analysis identified advanced cancer stage and optimal surgery as independent prognostic factors for PFS and OS. However, statin uses did not significantly impact PFS (adjusted HR 1.09; 95% CI 0.73, 1.64) or OS (adjusted HR 0.84; 95% CI 0.56, 1.27).</p><p><strong>Conclusion: </strong>Statin use was not associated with improved survival outcomes in patients with EOC. Future research, preferably through prospective randomized control trials, is warranted to minimize selection bias and further explore the potential benefits of statin in this context.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"414-425"},"PeriodicalIF":1.6000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of Statin Use on Survival Outcomes in Patients Diagnosed with Epithelial Ovarian Cancer.\",\"authors\":\"Pornpimon Nittiwatthanawit, Putsarat Insin, Putsarat Insin\",\"doi\":\"10.1159/000545430\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Patients diagnosed with epithelial ovarian cancer (EOC) usually experience a poor prognosis with a 5-year survival rate of approximately 40%. Thus, there would be an interest in a new perspective on the anticancer action of statins on survival outcomes in patients with EOC. This study aimed to assess the effect of statin on survival outcomes in patients diagnosed with EOC.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted on EOC patients scheduled for cytoreductive surgery at Rajavithi Hospital between January 2012 and December 2016. Data on statin use before being diagnosed with EOC and cancer treatment were extracted from medical records. Survival outcomes, including progression-free survival (PFS) and overall survival (OS), were analyzed using the Kaplan-Meier method and log-rank test, comparing statin users and non-users. The Cox proportional hazards model was employed to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs) to determine the association between statin use and survival outcomes.</p><p><strong>Results: </strong>A total of 477 EOC patients met the inclusion criteria. Among them, 76 (15.9%) were statin users, while 401 (84.1%) were non-users. Over a median follow-up of 59 months, 210 patients (44%) experienced disease recurrence, and 197 (41.3%) succumbed to EOC. There was no statistically significant difference between statin users and non-users between 5-year PFS (45.1% vs. 56.1%, p = 0.295) and 5-year OS (50.8% vs. 55.3%, p = 0.590). Multivariate Cox analysis identified advanced cancer stage and optimal surgery as independent prognostic factors for PFS and OS. However, statin uses did not significantly impact PFS (adjusted HR 1.09; 95% CI 0.73, 1.64) or OS (adjusted HR 0.84; 95% CI 0.56, 1.27).</p><p><strong>Conclusion: </strong>Statin use was not associated with improved survival outcomes in patients with EOC. Future research, preferably through prospective randomized control trials, is warranted to minimize selection bias and further explore the potential benefits of statin in this context.</p>\",\"PeriodicalId\":19543,\"journal\":{\"name\":\"Oncology Research and Treatment\",\"volume\":\" \",\"pages\":\"414-425\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology Research and Treatment\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000545430\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/21 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000545430","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
诊断为上皮性卵巢癌（EOC）的患者通常预后较差，5年生存率约为40%。因此，人们对他汀类药物对EOC患者生存结果的抗癌作用有了新的看法。本研究旨在评估他汀类药物对EOC患者生存结局的影响。方法：回顾性队列研究2012年1月至2016年12月在Rajavithi医院计划行细胞减少手术的EOC患者。从医疗记录中提取诊断为EOC和癌症治疗前的他汀类药物使用数据。生存结果，包括无进展生存期（PFS）和总生存期（OS），使用Kaplan-Meier方法和log-rank检验进行分析，比较他汀类药物使用者和非使用者。采用Cox比例风险模型来估计风险比（HR）和95%置信区间（95% ci），以确定他汀类药物使用与生存结果之间的关系。结果：共有477例EOC患者符合纳入标准。其中，他汀类药物使用者76人（15.9%），非他汀类药物使用者401人（84.1%）。在中位随访59个月期间，210名患者（44%）出现疾病复发，197名患者（41.3%）死于EOC。在5年PFS （45.1% vs. 56.1%, p=0.295）和5年OS （50.8% vs. 55.3%, p=0.590）之间，他汀类药物使用者和非使用者之间无统计学差异。多因素Cox分析发现，晚期癌症分期和最佳手术是PFS和OS的独立预后因素。然而，他汀类药物的使用并没有显著影响PFS(调整后的HR 1.09；95%CI 0.73,1.64)或OS(调整后HR 0.84；95% ci 0.56, 1.27)。结论：使用他汀类药物与改善EOC患者的生存结果无关。未来的研究，最好是通过前瞻性随机对照试验，以尽量减少选择偏差，并进一步探索他汀类药物在这种情况下的潜在益处。
Effect of Statin Use on Survival Outcomes in Patients Diagnosed with Epithelial Ovarian Cancer.
Introduction: Patients diagnosed with epithelial ovarian cancer (EOC) usually experience a poor prognosis with a 5-year survival rate of approximately 40%. Thus, there would be an interest in a new perspective on the anticancer action of statins on survival outcomes in patients with EOC. This study aimed to assess the effect of statin on survival outcomes in patients diagnosed with EOC.
Methods: A retrospective cohort study was conducted on EOC patients scheduled for cytoreductive surgery at Rajavithi Hospital between January 2012 and December 2016. Data on statin use before being diagnosed with EOC and cancer treatment were extracted from medical records. Survival outcomes, including progression-free survival (PFS) and overall survival (OS), were analyzed using the Kaplan-Meier method and log-rank test, comparing statin users and non-users. The Cox proportional hazards model was employed to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs) to determine the association between statin use and survival outcomes.
Results: A total of 477 EOC patients met the inclusion criteria. Among them, 76 (15.9%) were statin users, while 401 (84.1%) were non-users. Over a median follow-up of 59 months, 210 patients (44%) experienced disease recurrence, and 197 (41.3%) succumbed to EOC. There was no statistically significant difference between statin users and non-users between 5-year PFS (45.1% vs. 56.1%, p = 0.295) and 5-year OS (50.8% vs. 55.3%, p = 0.590). Multivariate Cox analysis identified advanced cancer stage and optimal surgery as independent prognostic factors for PFS and OS. However, statin uses did not significantly impact PFS (adjusted HR 1.09; 95% CI 0.73, 1.64) or OS (adjusted HR 0.84; 95% CI 0.56, 1.27).
Conclusion: Statin use was not associated with improved survival outcomes in patients with EOC. Future research, preferably through prospective randomized control trials, is warranted to minimize selection bias and further explore the potential benefits of statin in this context.
期刊介绍：
With the first issue in 2014, the journal ''Onkologie'' has changed its title to ''Oncology Research and Treatment''. By this change, publisher and editor set the scene for the further development of this interdisciplinary journal. The English title makes it clear that the articles are published in English – a logical step for the journal, which is listed in all relevant international databases. For excellent manuscripts, a ''Fast Track'' was introduced: The review is carried out within 2 weeks; after acceptance the papers are published online within 14 days and immediately released as ''Editor’s Choice'' to provide the authors with maximum visibility of their results. Interesting case reports are published in the section ''Novel Insights from Clinical Practice'' which clearly highlights the scientific advances which the report presents.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
